Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5488628 | 0.89 | GSK3A (0.39) | GSK3AGSK3BKMT2APOLBALDH1A1 | |
| SCHEMBL7468575 | 0.87 | KMT2A (0.46) | GSK3AGSK3BKMT2APOLBSMN1; SMN2 | |
| SCHEMBL7465028 | 0.85 | GSK3A (0.38) | GSK3AGSK3BKMT2APOLBSMN1; SMN2 | |
| SCHEMBL5486165 | 0.84 | GSK3A (0.36) | GSK3AGSK3BKMT2APOLBSMN1; SMN2 | |
| SCHEMBL5491448 | 0.83 | GSK3A (0.38) | GSK3AGSK3BRXRA | |
| SCHEMBL5487597 | 0.82 | GSK3A (0.36) | GSK3AGSK3BKMT2APOLBSMN1; SMN2 | |
| SCHEMBL7460353 | 0.80 | GSK3A (0.48) | GSK3AGSK3BKMT2APOLBALDH1A1 | |
| SCHEMBL7459946 | 0.80 | PIM1 (0.41) | GSK3AGSK3BKMT2APOLBALDH1A1 | |
| SCHEMBL7457132 | 0.80 | GSK3A (0.41) | GSK3AGSK3BKMT2APOLBSMN1; SMN2 | |
| SCHEMBL7463463 | 0.79 | GSK3A (0.40) | GSK3AGSK3BKMT2APOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515003-B1 | Useful in the treatment of diseases related to lipid and carbohydrate metabolism | MAXIA PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | claimed |
| EP-1214304-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | claimed |
| WO-2001016122-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| US-7226940-B2 | Substituted heterocycles for the treatment of diabetes and other diseases | INCYTE SAN DIEGO, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20060004059-A1 | Substituted heterocycles for the treatment of diabetes and other diseases | PFAHL MAGNUS | 2006-01-05 | — | — | US | disclosed |
| US-6974826-B2 | Imidazolidinedione derivatives for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC. (US) | 2005-12-13 | — | — | US | disclosed |
| EP-1593677-A2 | Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes | Incyte San Diego Incorporated (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1214304-B1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | INCYTE SAN DIEGO INC (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20050070581-A1 | Imidazolidinedione derivatives for the treatment of diabetes and other diseases | INCYTE SAN DIEGO, INC. | 2005-03-31 | — | — | US | disclosed |
| US-6765013-B2 | ANTIPROLIFERATIVE AGENTS FOR TREATING ADIPOCYTE DIFFERENTIATION, CANCER, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, CROHN'S DISEASE OR INFLAMMATORY BOWEL DISEASE | INCYTE SAN DIEGO | 2004-07-20 | — | — | US | disclosed |
| US-20030153606-A1 | Thiazolidinedione derivatives for the treatment of diabetes and other diseases | MAXIA PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| US-6515003-B1 | Useful in the treatment of diseases related to lipid and carbohydrate metabolism | MAXIA PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1214304-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001016122-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004059-A1 | Substituted heterocycles for the treatment of diabetes and other diseases | FABP4, HPGDS, GPR119 | GSK3A 1360/4885GSK3B 1164/4885KMT2A 1363/4885 |
| US-20030153606-A1 | Thiazolidinedione derivatives for the treatment of diabetes and other diseases | FABP4, PPARG, CPT2 | GSK3A 1003/4885GSK3B 774/4885KMT2A 1611/4885 |
| US-20050070581-A1 | Imidazolidinedione derivatives for the treatment of diabetes and other diseases | FABP4, GPR119, IL2 | GSK3A 1537/4885GSK3B 1261/4885KMT2A 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.